03 June 2004
Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products
Zofia Dzierżewicz, Beata Cwalina, Ludmiła Węglarz, Beata Wiśniowska, Joanna SzczerbaMed Sci Monit 2004; 10(6): BR185-190 :: ID: 11672
Abstract
Background:Desulfovibrio desulfuricans intestinal bacteria may contribute to toxic hydrogen sulfide production in the human gut. Our objective was to examine whether the D. desulfuricans strains isolated from the human body are susceptible to sulfasalazine (SAS) and the products of its biotransformation, i.e. 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), in order to determine the relationship between the strains’ susceptibility to SAS and their ability to reduce the azo bond within this drug.
Material/Methods: Six wild strains of D. desulfuricans (isolated from feces and biopsy specimens from patients with colitis ulcerosa, Crohn’s disease, irritable bowel syndrome, colonic diverticula, primary biliary cirrhosis, or tubular adenomas of the colon) were cultured in the presence of SAS, 5-ASA, and SP. Growth inhibition coefficients were compared with coefficients of inhibition of the azo-bond reduction in SAS.
Results: The D. desulfuricans strains present in the human digestive tract were susceptible to a small degree to SAS and to 5-ASA and SP.
Conclusions: The intestinal D. desulfuricans strains differed in their susceptibility to SAS and its biotransformation products. The strains showing higher susceptibility to SAS lost the ability to reduce the azo bond in this drug, which may be attributed to the lower metabolic activity of the bacteria. The presence of D. desulfuricans in the large intestines of patients with ulcerative colitis and the confirmed diversity of the biological activity of the isolated strains demonstrate the need for clinical examination of the role of these bacteria in the development of some inflammatory disorders.
Keywords: Biotransformation, Cell Division - drug effects, Desulfovibrio desulfuricans - cytology, Desulfovibrio desulfuricans - drug effects, Desulfovibrio desulfuricans - physiology, Drug Resistance, Bacterial, Intestines - microbiology, Mesalamine - pharmacology, Sulfapyridine - pharmacology, Sulfasalazine - metabolism, Sulfasalazine - pharmacology, Biotransformation, Cell Division - drug effects, Desulfovibrio desulfuricans - physiology, Drug Resistance, Bacterial, Intestines - microbiology, Mesalamine - pharmacology, Sulfapyridine - pharmacology, Sulfasalazine - pharmacology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952